Nov 2021: Den första kliniska prövningen av Sydkoreas hemodlade nästa generations chimära antigenreceptor T (CAR-T) cellterapi, som är utformad för att kringgå signaler från immunkontrollpunkten, har nyligen kommit igång.
Korea Advanced Institute of Science and Technology (KAIST) meddelade på onsdagen att en fas 1b klinisk prövning av dess CAR-T-cellterapi för närvarande genomförs vid Samsung Medical Center i Seoul. Försöket genomförs med 10 koreanska patienter som har återfall och refraktärt diffust stort B-cellslymfom. Marknadsföringsrättigheterna för pipelinen överfördes från universitetet till företaget Curocell, som var med och grundade av professor Kim Chan-hyuk. Curocell är ansvarig för revolutionärens kliniska utvecklingsprogram immunterapi.
In addition, a Phase 2 klinisk prövning involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for chimär antigenreceptor T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Du kanske vill läsa: CAR T-Cell terapi i Korea
Resultaten av studien presenterades i en artikel som publicerades online i oktobernumret av Molecular Therapy.
